Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis ...
Researcher warns that many .NET applications might be vulnerable to arbitrary file writes because .NET’s HTTP client proxy ...
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback